Long-Term Efficacy of Baricitinib in Alopecia Areata: 3-Year Results from BRAVE-AA1 and BRAVE-AA2

    September 2024 in “ Journal of the American Academy of Dermatology ”
    Maryanne M. Senna, Arash Mostaghimi, Manabu Ohyama, Rodney Sinclair, Chiara Chiasserini, Yves Dutronc, Najwa Somani, Guanglei Yu, Jill Kolodsick, Lucy Liu
    Image of study
    TLDR Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
    The study assessed the long-term efficacy of baricitinib in treating severe alopecia areata over three years, focusing on patients who responded positively at Week 52 with a SALT score of ≤20 (≤20% scalp hair loss). The results from the BRAVE-AA1 and BRAVE-AA2 trials demonstrated that continuous therapy with baricitinib, at doses of 4mg and 2mg, maintained significant hair regrowth in these patients, indicating sustained benefits of the treatment over an extended period.
    Discuss this study in the Community →

    Related

    1 / 1 results